Mechanistically, the bifunctional HDAC and PARP inhibitor induced “BRCAness,” thereby restoring synthetic lethality, reactivating STING expression, and promoting the infiltration and activation of T cells and dendritic cells in the tumor microenvironment. The gene discussed is PARP1; the disease is neoplasm.